

In the Claims:

Claims 1-60 (Cancelled)

- ①3 61. (Currently Amended) An isolated, recombinant polypeptide comprising a member selected from the group consisting of
- (a) the amino acid sequence of SEQ ID NO:2 ~~or SEQ ID NO:4~~; and
 - (b) an immunogenic polypeptide comprising a fragment sequence of at least 15 amino acids that matches an aligned contiguous segment of SEQ ID NO:2 ~~or SEQ ID NO:4~~;
- wherein the isolated, recombinant polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response to a polypeptide having the sequence of SEQ ID NO:2 ~~or SEQ ID NO:4~~.
62. (Currently Amended): The isolated, recombinant polypeptide of claim 61, wherein the polypeptide is according to (a).
63. (Currently Amended): The isolated, recombinant polypeptide of claim 61, wherein the polypeptide is according to (b).
64. (Currently Amended): The isolated, recombinant polypeptide of claim 61, wherein the immunogenic fragment of (b) comprises at least 20 amino acids.
65. (Currently Amended): The isolated, recombinant polypeptide of claim 61, wherein the isolated polypeptide consists of SEQ ID NO:2 ~~or SEQ ID NO:4~~.
66. (Currently Amended): A fusion protein comprising the isolated, recombinant polypeptide of Claim 61.

Q3
conclude
67. (Currently Amended) An immunogenic composition comprising the isolated,
recombinant polypeptide of Claim 61 and a pharmaceutically acceptable carrier.

68. (Previously Presented) The immunogenic composition of Claim 67, wherein said
immunogenic composition further comprises at least one other *Moraxella catarrhalis* antigen.
